ANTIDRUG ANTIBODIES AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH TNF-A-BLOKERS IN THE BULGARIAN POPULATION

Rheumatic diseases have a vast social and economic impact due to the percentage of the disabilities and due to the price of the drugs, used for their treatment. The effects of the antidrug antibodies can be divided in two aspects: loss of effect from the treatment and development of side effects. Both of the times the result is discontinuation of the treatment or treatment with non-effective and at the same time very expensive drug. For the rheumatologist it will be extremely important to find and prove the factors that influence the production of these antidrug antibodies. In this study we pay attention to the production of these antibodies and their correlation to the loss of the effect and/or increase in the disease activity indexes.